• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
The drug treatment of atrial fibrillation.心房颤动的药物治疗
Br J Clin Pharmacol. 1991 Sep;32(3):267-73. doi: 10.1111/j.1365-2125.1991.tb03898.x.
2
Pharmacologic management of atrial fibrillation: current therapeutic strategies.心房颤动的药物治疗:当前的治疗策略
Am Heart J. 2001 Feb;141(2 Suppl):S15-21. doi: 10.1067/mhj.2001.109952.
3
Canadian Cardiovascular Society atrial fibrillation guidelines 2010: rate and rhythm management.加拿大心血管学会 2010 年心房颤动指南:心率和节律管理。
Can J Cardiol. 2011 Jan-Feb;27(1):47-59. doi: 10.1016/j.cjca.2010.11.001.
4
Current management of symptomatic atrial fibrillation.症状性心房颤动的当前管理
Drugs. 2001;61(10):1425-37. doi: 10.2165/00003495-200161100-00006.
5
The pharmacologic treatment of atrial fibrillation.心房颤动的药物治疗
Cardiovasc Drugs Ther. 1991 Jun;5(3):617-28. doi: 10.1007/BF03029730.
6
[Pharmacologic treatment of atrial fibrillation].[心房颤动的药物治疗]
Pol Merkur Lekarski. 2008 Oct;25(148):303-8.
7
Rate control and sinus rhythm maintenance in atrial fibrillation: national trends in medication use, 1980-1996.心房颤动的心率控制与窦性心律维持:1980 - 1996年药物使用的全国趋势
Arch Intern Med. 1998 Oct 26;158(19):2144-8. doi: 10.1001/archinte.158.19.2144.
8
Rate control in atrial fibrillation.心房颤动的心率控制。
Lancet. 2016 Aug 20;388(10046):818-28. doi: 10.1016/S0140-6736(16)31258-2.
9
Atrial fibrillation: rate control often better than rhythm control.心房颤动:心率控制通常优于节律控制。
Prescrire Int. 2004 Apr;13(70):64-9.
10
[Medicinal rhythm control in atrial fibrillation].[心房颤动的药物节律控制]
Herzschrittmacherther Elektrophysiol. 2014 Mar;25(1):19-25. doi: 10.1007/s00399-014-0300-3. Epub 2014 Feb 19.

引用本文的文献

1
Rate control in permanent atrial fibrillation.永久性心房颤动的心率控制
BMJ. 2007 Nov 24;335(7629):1057-8. doi: 10.1136/bmj.39365.511076.BE.
2
Current management of symptomatic atrial fibrillation.症状性心房颤动的当前管理
Drugs. 2001;61(10):1425-37. doi: 10.2165/00003495-200161100-00006.
3
An open label, randomised, crossover study comparing sotalol and atenolol in the treatment of symptomatic paroxysmal atrial fibrillation.一项比较索他洛尔和阿替洛尔治疗症状性阵发性心房颤动的开放标签、随机、交叉研究。
Heart. 1999 Aug;82(2):170-5. doi: 10.1136/hrt.82.2.170.
4
Atrial fibrillation: a review of mechanism, etiology, and therapy.心房颤动:机制、病因及治疗综述
Clin Cardiol. 1997 Jul;20(7):640-50. doi: 10.1002/clc.4960200711.
5
ABC of atrial fibrillation. Drugs for atrial fibrillation.心房颤动基础知识。用于心房颤动的药物。
BMJ. 1995 Dec 16;311(7020):1631-4. doi: 10.1136/bmj.311.7020.1631.
6
Diltiazem. A review of its pharmacology and therapeutic use in older patients.地尔硫䓬。老年患者药理学及治疗应用综述。
Drugs Aging. 1993 Jul-Aug;3(4):363-90. doi: 10.2165/00002512-199303040-00007.

本文引用的文献

1
EFFECTS OF BETA-ADRENERGIC BLOCKADE WITH PROPRANOLOL IN PATIENTS WITH ATRIAL ARRHYTHMIAS.
N Engl J Med. 1965 Aug 19;273:410-5. doi: 10.1056/NEJM196508192730802.
2
Acute and chronic pharmacodynamic interaction of verapamil and digoxin in atrial fibrillation.维拉帕米与地高辛在心房颤动中的急性和慢性药效学相互作用。
Circulation. 1982 Jun;65(6):1163-70. doi: 10.1161/01.cir.65.6.1163.
3
The influence of verapamil on serum digoxin concentration.
Circulation. 1982 May;65(5):998-1003. doi: 10.1161/01.cir.65.5.998.
4
Thyrotoxic atrial fibrillation: an underdiagnosed condition?甲状腺毒症性心房颤动:一种诊断不足的疾病?
Br Med J (Clin Res Ed). 1982 Oct 2;285(6346):909-10. doi: 10.1136/bmj.285.6346.909.
5
Duration of atrial fibrillation and imminence of stroke: the Framingham study.心房颤动持续时间与卒中紧迫性:弗雷明汉研究
Stroke. 1983 Sep-Oct;14(5):664-7. doi: 10.1161/01.str.14.5.664.
6
Superiority of oral verapamil therapy to digoxin in treatment of chronic atrial fibrillation.口服维拉帕米治疗慢性心房颤动优于地高辛。
Chest. 1983 Mar;83(3):491-9. doi: 10.1378/chest.83.3.491.
7
Effects of nadolol on the spontaneous and exercise-provoked heart rate of patients with chronic atrial fibrillation receiving stable dosages of digoxin.
Am Heart J. 1984 Oct;108(4 Pt 2):1121-7. doi: 10.1016/0002-8703(84)90592-1.
8
Effect of Corwin (ICI 118587) on resting and exercise heart rate and exercise tolerance in digitalised patients with chronic atrial fibrillation.考温(ICI 118587)对慢性房颤洋地黄化患者静息及运动心率和运动耐量的影响。
Br Heart J. 1984 Oct;52(4):392-5. doi: 10.1136/hrt.52.4.392.
9
Plasma digoxin concentrations and digoxin toxicity in hospital patients.住院患者的血浆地高辛浓度与地高辛毒性
Br Heart J. 1971 Jul;33(4):540-5. doi: 10.1136/hrt.33.4.540.
10
Immediate effects of intravenous verapamil on atrial fibrillation.静脉注射维拉帕米对心房颤动的即刻影响。
Cardiovasc Res. 1971 Oct;5(4):419-24. doi: 10.1093/cvr/5.4.419.

心房颤动的药物治疗

The drug treatment of atrial fibrillation.

作者信息

Channer K S

机构信息

Department of Cardiology, Royal Hallamshire Hospital, Sheffield.

出版信息

Br J Clin Pharmacol. 1991 Sep;32(3):267-73. doi: 10.1111/j.1365-2125.1991.tb03898.x.

DOI:10.1111/j.1365-2125.1991.tb03898.x
PMID:1685662
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1368517/
Abstract
  1. Atrial fibrillation is an inefficient cardiac rhythm associated with impaired exercise tolerance, exertional dyspnoea, palpitation and a substantial risk of thromboembolism. 2. The first decision in management is to consider cardioversion which can be achieved in suitable cases electrically, or pharmacologically with a class Ic antiarrhythmic drug like flecainide or propafenone. 3. Prophylaxis in paroxysmal atrial fibrillation is best achieved with a class Ic drug or a class III drug such as sotalol or amiodarone. 4. Control of ventricular rate in chronic atrial fibrillation can be achieved by pharmacological manipulation of the atrioventricular node by digoxin alone, or in combination with the calcium channel blockers verapamil or diltiazem, or beta-adrenoceptor blockers with intrinsic sympathomimetic activity like pindolol or xamoterol. 5. In view of the considerable risk of thromboembolism in patients with chronic atrial fibrillation anticoagulation or at least treatment with aspirin should be considered.
摘要
  1. 心房颤动是一种低效的心律,与运动耐量受损、劳力性呼吸困难、心悸以及血栓栓塞的重大风险相关。2. 治疗的首要决策是考虑心脏复律,在合适的病例中可通过电复律实现,或使用如氟卡尼或普罗帕酮等Ic类抗心律失常药物进行药物复律。3. 阵发性心房颤动的预防最好使用Ic类药物或III类药物,如索他洛尔或胺碘酮。4. 慢性心房颤动时心室率的控制可通过单独使用地高辛对房室结进行药物调控来实现,或与钙通道阻滞剂维拉帕米或地尔硫䓬联合使用,或与具有内在拟交感活性的β肾上腺素受体阻滞剂如吲哚洛尔或扎莫特罗联合使用。5. 鉴于慢性心房颤动患者存在相当大的血栓栓塞风险,应考虑进行抗凝治疗或至少使用阿司匹林治疗。